Wendy B. Young Acquires 6,000 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock

Rapport Therapeutics (NASDAQ:RAPP) Director Wendy B. Young bought 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The stock was bought at an average price of $10.21 per share, with a total value of $61,260.00. Following the transaction, the director now directly owns 6,000 shares in the company, valued at $61,260. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Rapport Therapeutics Trading Up 4.9 %

NASDAQ:RAPP opened at $10.51 on Friday. Rapport Therapeutics has a twelve month low of $6.43 and a twelve month high of $29.74. The company has a 50-day moving average of $13.54 and a 200-day moving average of $18.73. The firm has a market cap of $383.57 million and a price-to-earnings ratio of -0.76.

Hedge Funds Weigh In On Rapport Therapeutics

Large investors have recently made changes to their positions in the business. BNP Paribas Financial Markets bought a new position in shares of Rapport Therapeutics during the 3rd quarter valued at about $34,000. KLP Kapitalforvaltning AS purchased a new stake in Rapport Therapeutics during the fourth quarter valued at about $34,000. Deutsche Bank AG purchased a new stake in Rapport Therapeutics during the fourth quarter valued at about $41,000. New York State Common Retirement Fund purchased a new stake in shares of Rapport Therapeutics in the fourth quarter worth approximately $62,000. Finally, Virtus ETF Advisers LLC purchased a new stake in shares of Rapport Therapeutics in the fourth quarter worth approximately $66,000.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.